{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:26:52Z","timestamp":1788877612201,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clml.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:14:55Z","timestamp":1752610495000},"page":"e865-e873.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Utility of Quantitative PET Parameters on Baseline and Interim FDG-PET Scans in Hodgkin Lymphoma"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8342-7563","authenticated-orcid":false,"given":"Natalia","family":"Kovaleva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-4302","authenticated-orcid":false,"given":"Shin Hnin","family":"Wai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Waters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3035-4147","authenticated-orcid":false,"given":"Hui Z.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2220-2570","authenticated-orcid":false,"given":"Oliver","family":"Piercey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-2559","authenticated-orcid":false,"given":"Eliza A.","family":"Hawkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4006-2380","authenticated-orcid":false,"given":"Geoffrey","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 4","key":"10.1016\/j.clml.2025.07.005_bib0001","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdf652","article-title":"Epidemiology and etiology of Hodgkin's lymphoma","volume":"13","author":"Thomas","year":"2002","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.clml.2025.07.005_bib0002","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood.2019003277","article-title":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial","volume":"135","author":"Sch\u00f6der","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2025.07.005_bib0003","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.2967\/jnumed.123.265871","article-title":"Validation of the \u0394SUVmax for interim PET interpretation in diffuse large B-cell lymphoma on the basis of the GAINED clinical trial","volume":"64","author":"Itti","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clml.2025.07.005_bib0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced Hodgkin Lymphoma trial","volume":"42","author":"Luminari","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.07.005_bib0005","article-title":"Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","author":"Trivella","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.clml.2025.07.005_bib0006","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma: a report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2025.07.005_bib0007","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","article-title":"Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study","volume":"34","author":"Zinzani","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.clml.2025.07.005_bib0008","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.clml.2025.07.005_bib0009","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.07.005_bib0010","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2967\/jnumed.109.073197","article-title":"18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma","volume":"51","author":"Cerci","year":"2010","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.clml.2025.07.005_bib0011","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Picardi","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.07.005_bib0012","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers15061760","article-title":"Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting","volume":"15","author":"Zheng","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.clml.2025.07.005_bib0013","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00277-023-05461-6","article-title":"Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin lymphoma","volume":"103","author":"Santos","year":"2023","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.07.005_bib0014","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2967\/jnumed.122.264740","article-title":"Prognostic value of 18F-FDG PET\/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen","volume":"64","author":"Michaud","year":"2022","journal-title":"J Nucl Med"},{"issue":"20","key":"10.1016\/j.clml.2025.07.005_bib0015","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"D\u00fchrsen","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.07.005_bib0016","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","article-title":"Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review","volume":"48","author":"Frood","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"50","key":"10.1016\/j.clml.2025.07.005_bib0017","doi-asserted-by":"crossref","first-page":"83544","DOI":"10.18632\/oncotarget.13180","article-title":"Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography\/computed tomography in diffuse large B-cell lymphoma","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2025.07.005_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6347404","article-title":"Radiomic features of 18F-FDG PET in Hodgkin lymphoma are predictive of outcomes","volume":"2021","author":"Zhou","year":"2021","journal-title":"Contrast Media Mol Imaging"},{"issue":"7","key":"10.1016\/j.clml.2025.07.005_bib0019","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.clml.2025.07.005_bib0020","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.clml.2025.07.005_bib0021","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.07.005_bib0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00277-019-03892-8","article-title":"The prognostic significance of \u0394SUVmax assessed by PET\/CT scan after 2 cycles of chemotherapy in patients with classic Hodgkin\u2019s lymphoma","volume":"99","author":"Yang","year":"2020","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.07.005_bib0023","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.clml.2025.07.005_bib0024","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1080\/10428194.2020.1855341","article-title":"SUVmax-based assessment of PET response shows a superior specificity to Deauville criteria for predicting recurrence in Hodgkin\u2019s lymphoma","volume":"62","author":"Texte","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2025.07.005_bib0025","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1053\/j.seminhematol.2024.06.002","article-title":"The role of response adapted therapy in the era of novel agents","volume":"61","author":"Schroers-Martin","year":"2024","journal-title":"Semin Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.07.005_bib0026","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1016\/S2352-3026(21)00102-2","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Straus","year":"2021","journal-title":"Lancet Haematol"},{"issue":"17","key":"10.1016\/j.clml.2025.07.005_bib0027","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002496?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002496?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:09:57Z","timestamp":1758604197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2152265025002496"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic Utility of Quantitative PET Parameters on Baseline and Interim FDG-PET Scans in Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}